



Press release

SHL announces change in Board Member

Tel Aviv/Zurich, 27 April 2015 - SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY), a leading provider and developer of advanced personal telemedicine solutions, today announced, that the Board of Directors has unanimously resolved to appoint Mr. Eli Alroy to serve as a member of the Board. In addition, Mr. Eli Ayalon has announced his resignation from the Board of Directors effective immediately. The Board extends its appreciation and thanks to Mr. Eli Ayalon for his service and contribution to the Company.

Mr. Eli Alroy is the Managing Director of A.Y.R.A.D. Investment Ltd. currently engaged in consulting services primarily in the field of real estate and investment activities. From 1994 to 2012, Mr. Alroy was the Chairman of the Supervisory Board of Globe Trade Centre S.A. (GTC), a Polish real estate development company traded on the Warsaw stock exchange. From 1994 to 1997, Mr. Alroy was the CEO of Kardan Real Estate, Enterprise and Development Ltd., Israel a real estate development company. Mr. Alroy currently serves as a board member of several companies notably Globalworth Real Estate Investments Limited (Guernsey) and Ofer Investments Ltd. (Israel). Mr. Alroy holds a B.Sc. (Cum Laude) from the civil engineering faculty at the Israel Institute of Technology (the Technion) and an M.Sc. in engineering from Stanford University. Nationality: Israeli.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, the United States and APAC in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: OTCPK: SMDCY. For more information please visit our web site at <http://www.shl-telemedicine.com>.

For further information please contact:

- Erez Alroy, Co-CEO, Phone: +972 3561 22 12, ereza@shl-telemedicine.com
- Martin Meier-Pfister, IRF Communications, Phone: +41 43 244 81 40, shl@irfcom.ch
- Garth Russell / Elizabeth Barker, KCSA Strategic Communications, (U.S.-based), Phone : +1 212 682 6300, Email : grussell@kcsa.com, ebarker@kcsa.com

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.